BTG3 and systemic lupus erythematosus: Evidence from murine SLE models has demonstrated that tofacitinib modulated lupus-associated parameters levels such as antinuclear antibody (ANA), anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibodies, proteinuria, skin rash, and type I IFN related responses.